SCHEMBL312640

SCHEMBL312640

c1cc2n(c1)CCCN2

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4299251 0.86
Hydrochloric Acid SCHEMBL2954628 0.68 MEN1 (0.31)
SCHEMBL21920713 0.65 KDM4E (0.41)
Hydrochloric Acid SCHEMBL21121451 0.64 GFER (0.36)
SCHEMBL24439824 0.60 KDM4E (0.32)
SCHEMBL1438685 0.59
SCHEMBL13294421 0.58 ALDH1A1 (0.41)
Hydrochloric Acid SCHEMBL7430822 0.56 GAA (0.48)
Hydrochloric Acid SCHEMBL11301415 0.55 CHKA (0.30)
SCHEMBL28096141 0.55

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 284 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12018030-B2 Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors VALO HEALTH, INC. (US) 2024-06-25 US claimed
CN-112088157-B Aryl-bipyridylamine derivatives as phosphatidylinositol phosphokinase inhibitors 拉文纳制药公司 2023-12-26 CN claimed
US-11739071-B2 Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors VALO HEALTH, INC. (US) 2023-08-29 US claimed
US-20210130321-A1 QUINAZOLINONES AND AZAQUINAZOLINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS VALO HEALTH, INC. 2021-05-06 US claimed
US-10889592-B2 Thienopyrazine carboxamides as ubiquitin-specific protease inhibitors VALO EARLY DISCOVERY, INC. (US) 2021-01-12 US claimed
US-8093246-B2 potent deoxycytidine kinase inhibitors; O-linked pyrimidin-4-amine-based compounds LEXICON PHARMACEUTICALS, INC. (US) 2012-01-10 US claimed
EP-2104672-A2 2-(PIPERIDIN-4-YL0XY)PYRIMIDIN-4-AMINE DERIVATIVES AS DEOXYCYTIDINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER Lexicon Pharmaceuticals, Inc. (US) 2009-09-30 EP claimed
WO-2008076779-A2 2-(PIPERIDIN-4-YL0XY)PYRIMIDIN-4-AMINE DERIVATIVES AS DEOXYCYTIDINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER LEXICON PHARMACEUTICALS, INC. (US) 2008-06-26 WO claimed
US-20080146571-A1 O-LINKED PYRIMIDIN-4-AMINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE TO TREAT CANCER OXFORD FINANCE LLC, AS COLLATERAL AGENT 2008-06-19 US claimed
US-12043623-B2 Purinones as ubiquitin-specific protease 1 inhibitors FORMA THERAPEUTICS, INC. (US) 2024-07-23 US disclosed
US-20240208960-A1 AMINOTHIAZOLE COMPOUNDS AS C-KIT INHIBITORS TAKEDA PHARMACEUTICALS U.S.A., INC. 2024-06-27 US disclosed
US-12018030-B2 Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors VALO HEALTH, INC. (US) 2024-06-25 US disclosed
US-20240199616-A1 BICYCLIC COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT 2024-06-20 US disclosed
US-20240174668-A1 PYRIDAZINE COMPOUNDS FOR INHIBITING NLRP3 VENTUS THERAPEUTICS U.S., INC. 2024-05-30 US disclosed
WO-2014164767-A1 NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN FORMA THERAPEUTICS, INC. (US) 2014-10-09 WO disclosed
WO-2014164749-A1 NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN FORMA THERAPEUTICS, INC. (US) 2014-10-09 WO disclosed
WO-2014141129-A2 NOVEL METHODS, COMPOUNDS, AND COMPOSITIONS FOR INHIBITION OF ROS GRUENEBERG DORRE A (US) 2014-09-18 WO disclosed
EP-1572113-A4 CALCIUM RECEPTOR MODULATING COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2006-11-22 EP disclosed
EP-1572113-A2 CALCIUM RECEPTOR MODULATING COMPOUND AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2005-09-14 EP disclosed
WO-2004017908-A2 CALCIUM RECEPTOR MODULATING COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-03-04 WO disclosed